Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01304173 · ClinicalTrials.gov registry record
Retrospective Chart Review of Valstar
A clinical trial of Carcinoma in Situ of Bladder, sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- 113
- Enrollment target
- 1
- Study location
NCT01304173: Completed study of Carcinoma in Situ of Bladder, sponsored by Endo Pharmaceuticals.
NCT01304173 is a study of Carcinoma in Situ of Bladder that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 113 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01304173, a study of Carcinoma in Situ of Bladder, has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- 113 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational study involving a retrospective review of medical records of adult patients who have been treated with intravesical valrubicin for bladder carcinoma in situ (CIS) since October 2009.
Primary Outcome
Event-free survival defined as recurrence, progression or death from any cause
Conditions Studied
Study Locations (1)
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-10 |
What the finished NCT01304173 record still lists
NCT01304173 is an observational study that tracks outcomes without assigning an intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Carcinoma in Situ of Bladder appearing as the primary indexed condition, and to 0 interventions.
NCT01304173 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT01304173 about?
NCT01304173 is a clinical study titled "Retrospective Chart Review of Valstar". This is an observational study involving a retrospective review of medical records of adult patients who have been treated with intravesical valrubicin for bladder carcinoma in situ (CIS) since October 2009.
What is the current status of trial NCT01304173?
This trial is currently completed. The enrollment target is 113 participants. The study started on 2011-03. Estimated completion is 2011-10.
What conditions does trial NCT01304173 study?
This clinical trial studies the following conditions: Carcinoma in Situ of Bladder.
Who is sponsoring clinical trial NCT01304173?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01304173 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia